Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECTRA trial of half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy
2016-004119-11Phase 4Active
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of eplerenone in Central Serous Chorioretinopathy (CSCR) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Complete resolution of subretinal fluid on OCT. Started Nov 2016; status: active.
02
Drugs
eplerenone
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on 2016-004119-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004119-11.